Skip to main content
18.218.37.5

Biocatalytic Continuous Manufacturing of Diabetes Drug: Plantwide Process Modeling, Optimization, and Environmental and Economic Analysis

By Ho, CH; Yi, JR; Wang, XN

Published on CMKC

Abstract

This work proposes a comprehensive framework of biocatalytic continuous manufacturing of sitagliptin, the active pharmaceutical ingredient of the leading dipeptidyl peptidase-4 inhibitor antidiabetic drug. Continuous manufacturing has the advantages of quality consistency, reduced waste generation, and cost-effectiveness in comparison to batch processes. Furthermore, compared to traditional catalysts, biocatalysts have lighter environmental footprints. An end-to-end continuous manufacturing process is designed and the reaction kinetics of the biocatalytic reaction is determined according to the published data. Based on the steady-state model of a plug-flow microreactor, the optimal productivity is determined to be 2.6 x 10(-2)mol h(-1) using surrogate-based optimization. In addition, an assessment of the process' environmental impacts demonstrates its sustainability with a lower E-factor of 53 compared to 200 of traditional processes. A comprehensive techno-economic analysis has also been performed, validating the economic feasibility of this process with a net present value of $150 million over a 20 year time period. Therefore, this present work demonstrates the feasibility, sustainability, and economic competitiveness of the proposed process.

Journal

ACS Sustainable Chemistry & Engineering. Volume 7, 2019, 1038-1051

DOI

10.1021/acssuschemeng.8b04673

Type of publication

Peer-reviewed journal

Affiliations

  • National University of Singapore
  • Massachusetts Institute of Technology (MIT) (MIT)

Article Classification

Research Article

Classification Areas

  • API

Tags